Search

Samah Alshehri, Mohannad Alshibani Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi ArabiaCorrespondence: Samah Alshehri, Department of Pharmacy Practice, King Abdulaziz University, P.O. Box 80200, Jeddah, 21589, Saudi Arabia, Tel +966564362332, Fax +12 9666400000. Ext. 20675, Email salshehri1@kau.edu.saIntroduction: There is a very limited information and studies on the impact of adherence to chronic obstructive pulmonary disease (COPD) medications in Saudi Arabia. We hypothesized that the adherence to COPD medication in our tertiary hospital is poor and can lead to frequent ED visits and longer hospitalization stays. The purpose of this study was to assess the impact of medication adherence in patients with COPD on emergency department (ED) visits and hospitalization.Methods: A single-center retrospective observational study included patients with a COPD exacerbation, who were admitted to a tertiary teaching hospital in Jeddah, Saudi Arabia from October 2017 to November 2020. The primary outcome was the rate of emergency department (ED) visit in one year. Secondary outcomes were hospitalization after ED visit and total hospital length of stay. Medication adherence was evaluated by using Fixed Medication Possession Ratio (FMPR). Patients with score of ≥ 0.80 were classified as high-adherent groups while patients with ratio < 0.80 were on low-adherent groups.Results: A total of 266 patients enrolled in the study. Of those 266 patients, 139 patients were on high-adherent group and 127 were on low-adherent group. There was a significant difference between the high-adherent group and low-adherent group in the incidence of ED visit in one year 62 (44.6%) vs 73 (57.5%); P < 0.036, and hospitalization after the ED visit 26 (18.7%) vs 42 (33.1%); P = 0.007. However, there was no significant difference between the two groups in the total hospital length of stay.Conclusion: Among patients with COPD, there was a significan

Majed S Al Yami,1,2 Mohammed Y Alzahrani,1,2 Abdulmajeed M Alshehri,1,2 Omar A Alshaya,1,2 Norah S Alsubiae,1 Yazeed M Alharbi,1 Latifah K Albaiahy,1 Mounira Aldeiban,1 Haya A Alkuait,3 Wejdan Alobaidi,4 Anas Aldawsari,5 Nouf M Almutairi,6 Mohannad Alshibani,7 Ghazwa B Korayem,8 Osamah M Alfayez,9 Abdulaali R Almutairi,10 Omar A Almohammed11 1Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; 3Sales Department, SPIMACO Addwaeih, Riyadh, Saudi Arabia; 4Sales Department,Novo Nordisk, Riyadh, Saudi Arabia; 5Sales Department,Sanofi, Riyadh, Saudi Arabia; 6Sales Department, BAYER Pharmaceutical, Riyadh, Saudi Arabia; 7Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; 8Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia; 9Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia; 10Drug Sector, Saudi Food and Drug Authority, Riyadh, Saudi Arabia; 11Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Ghazwa B KorayemPharmacy Practice Department, College of Pharmacy, Princess Nourah bint Abdulrahman University, Al Imam Abdullah Ibn Saud Ibn Abdul Aziz Road, Riyadh, Saudi ArabiaTel +966 504161649Email Gbkorayem@pnu.edu.saPurpose: The main objective of this study was to evaluate the effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism (VTE) in a “real-world” setting.Patients and Methods: A retrospective cohort study was conducted using data from a large tertiary hospital in Saudi Arabia. Patients were included if they were adults (≥ 18 years), diagnosed with VTE, and treated with either apixaban or warfarin between January 2016 and September 2018. Patients who had

Reem Bakraa,1 Ruba Aldhaheri,1 Mada Barashid,1 Sarah Benafeef,1 Maram Alzahrani,1 Rasha Bajaba,2 Samah Alshehri,3 Mohannad Alshibani3 1College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 2Laboratory and Blood Bank Department, King Fahd General Hospital, Jeddah, Saudi Arabia; 3Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi ArabiaCorrespondence: Mohannad AlshibaniDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, PO Box 22252, Jeddah, Saudi ArabiaTel +966 126400000 ext. 21146Fax +966 126951696Email malshibani@kau.edu.saBackground: Stroke is considered the second leading cause of death and the third leading cause of disability in the world. The incidence of stroke in Saudi Arabia is 43.8 per 100,000, due to the lack of knowledge and awareness of the population. This study intends to determine the level of stroke risk factor awareness among the Saudi population.Methods: A cross-sectional study was conducted in Saudi Arabia on 898 participants older than 18 years old. The validated online survey was randomly distributed and consisted of 20 questions in both English and Arabic languages to evaluate the level of awareness of stroke risk factors among the population.Results: A total of 898 participants completed the survey. The results showed that the median risk factor score was 5 (IQ 3– 8) out of 14. A total of 2.2% could recognize all 14 risk factors. Personal history of hypertension was chosen as a risk factor by the majority of the participants (81.7%) followed by personal history of stroke (74.1%) and personal history of dyslipidemia (57.2%).Conclusion: This study showed that there is an insufficient level of stroke risk factor awareness in Saudi Arabia. More than half of the participants identified the term (stroke), while only 2.2% could recognize all 14 risk factors. Hence, public education is needed to identify people with stroke risk factors.Keywords: stroke, awarene